Skip to main content
. 2021 May 18;26(7):e1250–e1255. doi: 10.1002/onco.13805

Table 2.

Summary of the clinical safety data in Study 002 and Study 001

Adverse event type Study 002 (n = 21), n (%) Study 001 (n = 9), n (%)
All adverse events 21 (100) 9 (100)
Adverse events of grade 3 or higher 18 (85.7) 3 (33.3)
Adverse events leading to death 0 0
Serious adverse events 1 (4.8) 1 (11.1)
Adverse events leading to treatment discontinuation 0 0